MESO Similar Chart Price Prediction
The price of MESO is predicted to go up 14.24%, based on the high correlation periods with BFH. The similarity of these two price pattern on the periods is 93.08%.
MESO
BFH
Up: 14.24%Similarity: 93.08%
MESO Revenue Forecast
MESO EPS Forecast
MESO FAQs
What is bull’s view on MESO?
What is bear's view on MESO?
What is MESO revenue forecast for next quarter？
MESO Analyst's Forecast
David Stanton
Jefferies
Strong Buy → Hold
2024-12-23
Price Target
n/a
Downside
0%
Jefferies downgraded Mesoblast to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company's for the FDA'ss recent approval of Ryoncil in pediatric steroids-refractory acute graft-versus-host disease patients. While the market size is only 375 pediatric patients per year in the U.S., expansion of this indication is possible in adults if the upcoming adult trial is positive, the analyst tells investors in a research note. Jefferies continues to assume full U.S. reimbursement approval at the start of fiscal 2026. However, after Mesoblast's recent share price appreciation, the firm downgraded the shares on valuation.
Jason McCarthy
Maxim Group
Hold → Strong Buy
2024-09-24
Price Target
$12
Upside
+65.06%
